Make the profile of
DrugBank yours.

Company description

DrugBank is a biomedical intelligence platform built on over 20 years of curated, structured drug knowledge. Originally developed at the University of Alberta by co-founders Craig Knox and Michael Wilson, the platform began as a database of 4,000 drugs and their biological targets and has since grown into a comprehensive intelligence operating system for the biopharma industry. DrugBank connects scientific and commercial data across drugs, targets, diseases, clinical trials, and companies, supporting workflows from early drug discovery through to clinical decision-making.

DrugBank serves enterprise biopharma and healthtech organizations, as well as clinical software providers and academic research institutions. Nine of the top 20 global pharmaceutical companies rely on DrugBank, and the platform has been cited in over 58,000 scientific publications, with more than $4 billion in global research enabled by its data. A Head of Bioinformatics at a top-15 pharma company has noted that DrugBank shortened the time taken to validate new drug targets by a factor of 5 to 10 times.

Core Products and Access Modes

• API / MCP: Programmatic access to DrugBank's knowledgebase for integration into internal platforms, pipelines, and applications.
• Intelligence Interface: A user-facing interface for exploring and querying drug, target, disease, trial, and company relationships.
• AI/ML-Ready Datasets: Structured, ontology-mapped datasets designed for use in machine learning model training and data science workflows.
• Clinical Intelligence API: An evidence-based API for integration into healthcare software, providing structured drug information and a drug-drug interaction checker to support clinical decision support and patient safety.
• Academic Data Access: Accessible-rate academic licenses for non-commercial research, used by over 1,500 research institutions worldwide.

Key Use Cases

• Asset and target prioritization: Evaluating scientific defensibility, clinical correlation, and competitive positioning to identify opportunities with the highest probability of success.
• Competitive and landscape intelligence: Monitoring pipeline activity, trial data, and competitor developments across therapeutic areas to assess emerging opportunities and risks.
• Mechanism and pathway exploration: Exploring drug-target-disease relationships to identify novel mechanisms of action, drug repurposing opportunities, and underexplored biology.
• Model training and AI/ML enablement: Supplying structured, ontology-mapped data to power internal proprietary platforms and machine learning models.

Teams Served

• Business Development and Licensing: Supporting evaluation of partnership and in-licensing opportunities using unified scientific and commercial data to inform deal decisions.
• Data Science and Informatics: Providing structured, ontology-mapped datasets that reduce data preparation time and integrate readily into models and internal platforms.
• Translational Medicine: Connecting preclinical, clinical, and patient data across therapeutic areas to support target validation and go/no-go decisions.
• Competitive Intelligence: Delivering continuously updated pipeline activity, trial updates, and competitor intelligence across therapeutic areas from a single platform.

Notable Partnerships and Integrations

• EvE Bio: A commercial sponsorship integrating EvE Bio's pharmome-mapping data — comprising 385,572 confirmed drug-target interactions across 159 validated targets — into the DrugBank intelligence platform.
• American Society of Health-System Pharmacists (ASHP): A partnership combining both organizations' data capabilities, with scope for product development collaborations to address gaps in the industry.

Leadership

• Lisa Downey, CEO: A life sciences and health data executive with over 20 years of experience scaling and commercializing biomedical data platforms across real-world data, genomics, and pharma.
• Mike Wilson, CPO and Co-founder: One of the most highly cited researchers in bioinformatics, leading product vision focused on translating complex science into decision-driving tools.
• Craig Knox, CTO and Co-founder: A bioinformatics expert who has architected globally recognized biomedical databases including DrugBank and HMDB, with a focus on data quality, scale, and scientific rigor.

DrugBank offers free account access for exploring drug profiles, alongside enterprise and academic licensing options. The platform continues to expand its AI-driven capabilities and data partnerships as it moves into its next phase of development.

AI-generated · replace with your own

Software attributed to DrugBank

• DrugBank Biopharma Intelligence Operating SystemView
• DrugBank Data LibraryView
• DrugBank Clinical APIView

Edit all with premium access